Zealand Pharma expands management team
Danish biopharmaceutical firm makes three senior appointments
"Together they bring a wealth of experience, energy and skills to Zealand Pharma as we continue to advance our growth strategy," said David Horn Solomon, chief executive of Zealand Pharma.
Grondahl starts on 1 April, joining the firm from Novo Nordisk, where until recently he was corporate vice president for strategic alliances.
Blom, who joined the company earlier this month, was cfo of Swedish Orphan International, which recently merged with Biovitrum to form Swedish Orphan-Biovitrum of Stockholm.
Hyttel, who became senior vice president for operations on 1 March, founded Zealand Pharma in 1998. He worked for H Lundbeck for 30 years prior to joining Zealand.
Zealand's most advanced project, Lixisenatide (ZP10/AVE0010), a GLP-1 agonist for the treatment of Type II diabetes has been out licensed to Sanofi-Aventis of France. Sanofi-Aventis is completing 9 Phase III trials with first results to be released in June. Sanofi-Aventis is also commercialising a Lantus-Lixisenatide combination product for the treatment of Type II diabetes that has completed Phase I clinical studies. Submission of IND/MAA for Lixisenatide is expected in 2011.
You may also like
Research & Development
Dual inhibition of motor proteins KIF18A and CENP-E shown to selectively kill cancer cells
Researchers from Osaka University and MIT have discovered that blocking two cooperative motor proteins involved in chromosome alignment can trigger cancer cell death, revealing a promising new target for anticancer therapies
Research & Development
Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development
Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies